Verseon Receives European Patent for Innovative Thrombin Inhibitors

January 12, 2021

The company now has 82 patents in 11 patent families

Fremont, Calif.—Verseon announced today that it has received yet another patent from the European Patent Office related to its novel class of direct thrombin inhibitors. Having created chemical matter never before synthesized, the company foresees applications for this family of compounds in anticoagulation, atrial fibrillation, deep-vein thrombosis, pulmonary embolisms, acute coronary syndrome, coronary artery disease, cancer, neuropathic pain, and fibrosis.

Verseon also received 16 patents for its various drug compound families in 2020. These patents cover composition of matter, method of use, or both. Jurisdictions issuing patents to Verseon include Israel, Japan, Korea, Mexico, and the European Union. The receipt of these patents marks a milestone for several of Verseon’s drug programs. It also reflects the power of Verseon’s drug-discovery platform to produce valuable novel intellectual property. These compounds include serine protease inhibitors for various ongoing drug-development programs. Other compounds demonstrated promise for additional drug programs that will officially launch in 2021 and 2022. “It’s gratifying to see the platform we built generating so many novel therapeutic compounds,” said CEO Adityo Prakash. “The efficiency with which our platform generates new molecules will increase our IP portfolio severalfold over the next few years and create treatment options not previously available to patients.”

Over the course of the past decade, Verseon has developed the world’s most accurate and precise computational drug design platform to underpin the development of its IP. The company’s development team have also become the world’s foremost experts on serine proteases since the launch of its first program. And its extensive library of scaffolds for serine protease inhibitors continues to grow, along with libraries of other compounds that cannot be developed with any other platform in the industry. The EPO utility patent increases the total number of patents the company has received in various jurisdictions to 82 patents, spanning 5 technology and 6 drug patent families.

About Verseon

To advance global health, Verseon International Corporation ( has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company’s drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and advanced AI to develop drug compounds that have never before been synthesized—and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.

Back to News